A dissolving film could become the first oral rescue medicine for severe allergies.
Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.
How this was made
The 30-second read
Why it matters
The NDA resubmission is a fresh regulatory milestone that could materially affect AQST's valuation ahead of the March 2027 PDUFA deadline.
Market read
Regulatory progress for a novel allergy treatment creates a near‑term trading catalyst for AQST and may set a precedent for oral epinephrine products.
What to watch
The commercial launch timeline and reimbursement landscape remain uncertain, which could limit upside
Background
Aquestive Therapeutics provided a Q3 2026 financial update and detailed its pipeline, highlighting the Anaphylm oral rescue medication as a key upcoming product.
Ticker impact
AQST announced resubmission of its Anaphylm NDA to the FDA with a PDUFA goal date of March 16, 2027, marking the first public disclosure of this regulatory step.
likely upside as investors price in potential approval and market entry
Regulatory progress for a first‑in‑class oral epinephrine product is material for a biotech; the market typically reacts positively to forward‑looking FDA milestones.
Market effects
strengthens the allergy‑treatment sub‑sector and may boost peer biotech valuations
U.S. biotech market sees added upside; Canadian and EU markets watch for parallel filings
potentially influences global allergy‑medication pipelines and related specialty pharma stocks
Counterpoint
If the FDA raises additional concerns, the stock could face a sharp decline despite the resubmission
Key entities
- companyAquestive Therapeutics, Inc.
Biopharmaceutical company developing oral epinephrine products
- executiveDaniel Barber
President and CEO of Aquestive, quoted on the FDA resubmission


